Are you going to #ASH25, the annual meeting of the American Society of Hematology? STAT is - and we're hosting one of our amazing live events featuring @adamfeuerstein, @damiangarde, and @kathmacphail -- as well as executives and physicians from $JNJ, $GILD, $BMY, Blood Cancer United.. and ASH! The event is Friday night. It will feature: Damian interviewing J&J exec Yusri Elsayed and research veteran Lore Gruenbaum about why hematology is oncology's breakthrough foundry; Katherine interviewing Bethany Samuelson Bannow, an ASH researcher able to look out over the hematology field -- and who's own research recently went viral; And Adam interviewing Lynelle B. Hoch from $BMY and Cindy Perettie from Kite about the future of CAR-T. There will be food, drinks, and great company. If you're in Orlando, check it out! You can sign up here: statnews.com/event/stat-at-a…

It's the incredible shrinking Moderna. This morning's absolute must read, whether you are in biotech or not is my colleague @Jasonmmast on the rise and fall --and maybe rise again? -- of the biotech firm that seemed to dominate the world just a few years ago. Jason interviewed two dozen current and former Moderna employees, and pushed the company to talk. The details are scintillating: overspending on clinical trials, boasting that the company would have a dozen drugs, overestimating sales... and hiring Maroon 5 to play a party. Now, the department of Health and Human Services, which helped build the company, seems to have turned on it. It's a story of the double-edged sword of the bravado and risk-taking that often drive entrepreneurship, of the backlash against vaccines, and of the hard fact that even if you have billions of dollars you can spend them Give it a read: statnews.com/2025/10/30/mode…

Well. I have the absolute best news for fans of @statnews. Quite simply: @damiangarde is returning. Damian will be working with me on STAT's events, including our Summits. He'll also be writing the kind of amazing profiles that are his stock in trade. I'll include a few in a thread after this post in case you haven't read them, in which case you are in for a treat. Damian's one of the most fluid and creative writers I have ever worked with, and he knows the biopharma industry like few others. He shared a Polk Award with @adamfeuerstein and me for STAT's reporting on controversies around the Alzheimer's drug aducanumab, and I can tell you that story relied not only on his skill as a writer but on his incredible ability to get sources to open up. He was also a person who added heart and soul to STAT -- it's really difficult to have an argument with anyone when Damian is around. I can't wait to work with him again. I'm really, really excited. Welcome home.